2 Nov 2011: Huynh C, Poliseno L, Segura MF, Medicherla R, Haimovic A, et al. (2011) Correction: The Novel Gamma Secretase Inhibitor RO4929097 Reduces the Tumor Initiating Potential of Melanoma. PLOS ONE 6(11): 10.1371/annotation/a89c089f-ae9d-4453-a314-37efd5efb126. https://doi.org/10.1371/annotation/a89c089f-ae9d-4453-a314-37efd5efb126 View correction
Several reports have demonstrated a role for aberrant NOTCH signaling in melanoma genesis and progression, prompting us to explore if targeting this pathway is a valid therapeutic approach against melanoma. We targeted NOTCH signaling using RO4929097, a novel inhibitor of gamma secretase, which is a key component of the enzymatic complex that cleaves and activates NOTCH. The effects of RO4929097 on the oncogenic and stem cell properties of a panel of melanoma cell lines were tested both in vitro and in vivo, using xenograft models. In human primary melanoma cell lines, RO4929097 decreased the levels of NOTCH transcriptional target HES1. This was accompanied by reduced proliferation and impaired ability to form colonies in soft agar and to organize in tridimensional spheres. Moreover, RO4929097 affected the growth of human primary melanoma xenograft in NOD/SCID/IL2gammaR-/- mice and inhibited subsequent tumor formation in a serial xenotransplantation model, suggesting that inhibition of NOTCH signaling suppresses the tumor initiating potential of melanoma cells. In addition, RO4929097 decreased tumor volume and blocked the invasive growth pattern of metastatic melanoma cell lines in vivo. Finally, increased gene expression of NOTCH signaling components correlated with shorter post recurrence survival in metastatic melanoma cases. Our data support NOTCH inhibition as a promising therapeutic strategy against melanoma.
Citation: Huynh C, Poliseno L, Segura MF, Medicherla R, Haimovic A, Menendez S, et al. (2011) The Novel Gamma Secretase Inhibitor RO4929097 Reduces the Tumor Initiating Potential of Melanoma. PLoS ONE 6(9): e25264. https://doi.org/10.1371/journal.pone.0025264
Editor: Roger Chammas, Faculdade de Medicina, Universidade de São Paulo, Brazil
Received: July 21, 2011; Accepted: August 29, 2011; Published: September 29, 2011
Copyright: © 2011 Huynh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: CH has been supported by the New York University Physician Scientist Training Program, a National Cancer Center Postdoctoral fellowship and the National Institute of Health T32 CA09454-19 fellowship training grant. MFS is supported by a National Cancer Center Postdoctoral fellowship. This work was funded by the New York University CCGS support grant (5 P30 CA016087), Chemotherapy Foundation and the Marc Jacobs campaign to support melanoma research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: JFB is a former employee of Hoffmann-La Roche Inc. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
The incidence of melanoma has been constantly increasing during the last decades . Adjuvant therapy after complete resection is recommended for thick primary melanoma with lymph node metastases, because recurrence rates are relatively high and overall survival is poor . However, IFNalpha remains the only approved adjuvant therapy, which provides a modest disease-free survival benefit . Furthermore, it is especially concerning that the conventionally used drugs for metastatic melanoma include dacarbazine and IL-2, both of which cause poor (<15% of cases) and transient responses . Although promising therapeutic responses have been observed in recent clinical trials using the BRAF inhibitor Vemurafenib (PLX4032) and the monoclonal antibody against CTLA-4 Ipilimumab, both recently approved by the FDA, emergence of resistance and severe side effects have already been confronted , , , , , .
The NOTCH signaling pathway, which plays a role in organogenesis and cell fate determination during embryogenesis, involves four NOTCH transmembrane receptors (NOTCH 1-4) . Binding of DELTA (DLL 1/3/4) or JAGGED (JAG 1/2) ligands makes the receptors susceptible to metalloprotease- and gamma secretase-mediated proteolytic cleavage. This cleavage results in the release of NOTCH intracellular domain (NIC) from the plasma membrane and its translocation into the nucleus. Here, NIC mediates the transcription of target genes, including basic helix-loop-helix transcription factors of the hairy and enhancer of split (HES) family and the HES-related repressor protein (HERP/HRT/HEY) family.
Aberrant NOTCH signaling has been recently linked to many malignancies including melanoma, where it plays a role in progression and possibly in development , . Mechanistically, NOTCH signaling relies on crosstalk with the Wnt/β-catenin, the MAPK/AKT, the BRN2/MITF and the NODAL pathways in order to elicit its biological functions , , , , .
Aberrant NOTCH signaling has also been shown to confer stem cell-like properties in different cancer types, such as breast cancer and glioma (reviewed in ref. ). Identification of stem cell-like tumor initiating cells has been of major interest in melanoma. Although there is an ongoing debate about the frequency and identity of melanoma initiating cells , , , , , the inability to eradicate this subpopulation is thought to be a reason for the failure of current treatment strategies . Therefore, NOTCH inhibition in melanoma, possibly through the targeting of tumor initiating cells, can be foreseen as a new and promising therapeutic strategy.
Essential to NOTCH signaling is the catalytic cleavage of NOTCH receptor by the gamma secretase complex. Different inhibitors of gamma secretase have been developed (see ref.  for a list). These inhibitors have been tested in vitro on a variety of cell lines, including melanoma , , , . Clinical data have been supplied mostly by trials in adult T Cell leukemia (ALL), but efficacy has been hindered by significant gastrointestinal toxicities associated with treatment . However, RO4929097 is a novel gamma secretase inhibitor with an improved clinical toxicity profile . Here, we report the preclinical effects of RO4929097 on both primary and metastatic melanoma cells. In particular, we show for the first time that the inhibition of NOTCH signaling has an impact on the tumor initiating properties of melanoma cells.
RO4929097 affects the oncogenic and stem cell-like properties of primary melanoma cells in vitro
In order to evaluate the potential use of RO4929097 in the adjuvant setting, the drug was initially tested on a panel of primary melanoma cell lines. WM35, WM98.1, WM115, WM983A and WM3248 were chosen because of their aggressive phenotype, as indicated by their ability to form colonies in soft agar and to organize in spheres (Figure S1), which are nonadherent 3D structures enriched in melanoma initiating cells and characterized by increased differentiation capacity in vitro and tumorigenic potential in vivo , .
Upon RO4929097 treatment, the selected melanoma cell lines showed downregulation of NOTCH downstream effector HES1 (Figure 1A), confirming the ability of the drug to affect the NOTCH signaling pathway. The impairment of NOTCH signaling was associated with a significant reduction in cell proliferation (Figure 1B) and in anchorage independent growth (Figure 1C). We then tested the ability of RO4929097 to impair the formation of melanospheres. We indeed found a decrease in the amount of melanospheres formed upon RO4929097 treatment in primary melanoma cell lines (Figure 1D).
(A) RO4929097 causes a decrease in the levels of NOTCH downstream target HES1. WM35, WM98.1, WM115, WM983A and WM3248 cells were treated with DMSO (white bars) or 10 uM RO492907 (black bars) for 24 h. At that time, RNA was collected and HES1 levels were measured by qRT-PCR. The mean±s.d. of 3 independent experiments is reported. (B) RO4929097 inhibits cell proliferation. The indicated cell lines were treated with DMSO (white circles) or 10 uM RO4929097 (black circles). A representative curve of three independent experiments is reported. (C) RO4929097 inhibits anchorage independent growth. White bars: DMSO treated cells; black bars: RO4929097 treated cells. The mean±s.d. of three independent experiments is reported. Right panels show representative images of WM983A cells. (D) RO4929097 impairs the formation of melanospheres. Representative pictures of one among 3 independent experiments are shown. T test, *p<0.05; **p<0.005; ***p<0.001.
Taken together these results suggest that RO4929097 is able to affect the oncogenic and stem cell-like properties of melanoma cells in vitro.
RO4929097 impairs the growth of primary melanoma cells in vivo
To further validate the effects of NOTCH pathway inhibition, we investigated the effects of RO4929097 on the growth of the primary melanoma cell line WM3248 in NOD/SCID/IL2gammaR-/- (NOG) mice. Once measurable tumors were established, we randomly distributed the mice into groups to receive either vehicle control or RO4929097 by daily oral administration (Figure S2A). In accordance with our in vitro data, we found a decrease in tumor growth with RO4929097 treatment, which was more appreciable after tumors were extracted for weight assessment (Figure 2A, B). RO4929097-treated tumors also displayed lower expression of putative melanoma stem cell markers CD166, CD271 and JARID1B , ,  compared to vehicle-treated ones (Figure 2C). In order to formally prove that the decrease in these markers is associated with a diminished tumor-initiating ability, we used a serial xenotransplantation assay . We resected primary tumors from RO4929097- or vehicle-treated mice and dissociated the cells for re-implantation into NOG mice. We compared two different cellular concentrations, 105 and 104 cells per flank. Secondary tumors did not receive any further treatment with either vehicle or RO4929097, while their intrinsic growth properties were monitored (Figure S2A). At the concentration of 105 injected cells per flank, we did not find a significant difference between vehicle- and RO4929097-treated cells in time to secondary tumor formation. However, the percentage of secondary tumors formed by RO4929097-treated cells was lower (Figure 2D, left). Furthermore, the secondary tumors formed by RO4929097-treated cells were smaller (Figure 2E, F). Strikingly, a significant delay in tumor formation by the RO4929097-treated cells compared to the vehicle-treated ones was observed in mice injected with 104 cells (Figure 2D, right). Nearly 40 days after implantation, only 1/8 flanks injected with RO4929097-treated cells had developed measurable tumors as compared to 6/8 injected with vehicle-treated cells. All together these results indicate that RO4929097 is able to affect the tumorigenic potential of melanoma cells in vivo.
(A–C) Primary tumor formation of vehicle- and RO4929097-treated WM3248 cells. (A) 5×106 WM3248 primary melanoma cells were injected in the flank of NOG mice (n = 20). Once the tumors became measurable, mice were randomized in two groups and vehicle (n = 10) or RO4929097 (n = 10) was administered orally at 10 mg/Kg/day for 30 days. Tumor volume was measured every 2–3 days. White circles: vehicle-treated mice; black circles: RO4929097-treated mice. (B) At the end of the treatment period, tumors were excised and weighed. White bar: vehicle-treated mice; black bar: RO4929097-treated mice. (C) Levels of melanoma stem cell markers CD166, CD271 and JARID1B in WM3248 xenografts measured by qRT-PCR. White bars: vehicle-treated tumors; black bars: RO4929097-treated tumors. (D–F) Secondary tumor formation of vehicle and RO4929097-treated WM3248 cells. (D) White bars: secondary tumors formed by vehicle-treated primary tumors; black bars: secondary tumors formed by RO4929097-treated primary tumors. (E) Volume and (F) weight of the secondary tumors formed by 105 WM3248 cells previously treated with vehicle (white circles/bar) or RO4929097 (black circles/bar). Tumor volume was measured every 2–3 days starting at 30 days post injection. At 45 days after the injection, tumors were excised and the weight was measured. T test, *p<0.05; **p<0.005; ***p<0.001.
RO4929097 impairs the growth of metastatic melanoma cells in vivo
We also tested the effects of RO4929097 on metastatic melanoma cell lines using two in vivo xenograft models. We first assessed the impact of RO4929097 on tumor onset by treating NOG mice with the compound for 12 days, starting 7 days after flank injection of 5B1 melanoma cells (Figure S2B). In this experimental setting, we found a significant delay in tumor formation in RO4929097-treated mice compared to vehicle treated ones (Figure 3A). RO4929097-treated tumors were characterized by reduced proliferative index, as revealed by Ki-67 staining (Figure 3B). We then assessed the impact of RO4929097 treatment on the growth of pre-existing tumors, by initiating the treatment only after measurable tumors were established (Figure S2C). RO4929097 treatment negatively affected the volume (Figure 3C) and especially the weight (Figure 3D) of A375 tumors xenografted into NOG mice, without increasing the number of apoptotic cells (Caspase 3 staining on resected tumors, not shown). A different in vivo growth pattern associated with RO4929097 treatment was also observed: compound-treated tumors grew along the subcutaneous dermal borders, as opposed to vehicle-treated tumors that consistently invaded the peritoneum (Figure 3E). The expression of the NOTCH targets HES1 and HEY1 was reduced in RO4929097-treated tumors, together with that of putative melanoma stem cell markers (Figure 3F). Previous studies have shown significant toxicity, particularly secretory diarrhea, associated with gamma secretase inhibition. In contrast, we did not observe any significant weight changes or overt abnormalities in the organs of RO4929097-treated mice compared to vehicle-treated ones (Figure S3).
(A–B) 106 5B1 metastatic melanoma cells were injected in the flank of NOG mice (n = 20). Before tumors became measurable, mice were randomized in two groups and vehicle (n = 10) or RO4929097 (n = 10) was administered orally at 10 mg/Kg/day for 12 days. (A) Tumor volume, measured every 2–3 days starting 3 days after the end of the treatment. White circles: vehicle-treated mice; black circles: RO4929097-treated mice. (B) Percentage of Ki-67-positive cells in vehicle-treated (white circles) and RO4929097-treated (black circles) tumors. Immunohistochemistry was performed on tumor excised twenty-five days after the end of the treatment. (C–F) 2×106 A375 metastatic melanoma cells were injected in the flanks of NOG mice (n = 12). As soon as tumors became measurable, mice were randomized in two groups, and vehicle (n = 6) or RO4929097 (n = 6) was administered orally at 10 mg/Kg/day for 2 weeks. (C) Tumor volume, measured every 2–3 days during the two weeks of treatment. White circles: vehicle-treated mice; black circles: RO4929097-treated mice. (D) Tumor weight, measured when the tumors were excised at the end of the 2 weeks of treatment. White bar: vehicle-treated mice; black bar: RO4929097-treated mice. (E) Invasive features (dermal attachment versus peritoneal invasion) of vehicle-treated and RO4929097-treated tumors. (F) qRT-PCR analysis of NOTCH downstream effectors HES1 and HEY1 and of melanoma stem cell markers CD166, CD271 and JARID1B in vehicle-treated (white bars) and RO4929097-treated (black bars) tumors. T test, *p<0.05; **p<0.005; ***p<0.001.
NOTCH activity predicts melanoma patient outcome
The analysis of gene expression arrays recently published by our group and others , ,  shows that several NOTCH signaling pathway components are overexpressed in primary as well as in metastatic melanoma compared to melanocytic controls (Figure 4A and Figure S4), confirming the notion that NOTCH signaling pathway is upregulated in melanoma , . However, to our knowledge, a potential association between aberrant NOTCH signaling and prognosis in melanoma patients has not been shown. Using the Affymetrix expression profile of 44 metastatic melanoma samples from patients followed clinically for a median of 20 months (2–38 months range) , we examined whether NOTCH signaling components can be prognostic markers in metastatic melanoma. We indeed found that higher HES1 and DLL3 levels were significantly associated with decreased post recurrence survival as continuous predictors in Cox regression analysis (Figure 4B).
(A) mRNA array analysis of NOTCH pathway members. Affymetrix U133A 2.0 array performed on 4 melanocyte controls (2 normal human melanocytes and 2 immortalized melanocytes), 4 primary and 14 metastatic cell lines  reveals the upregulation of NOTCH pathway members, such as JAG1, JAG2, DLL3, NOTCH3, HES1, HES2, HEY1 and HEY2 in melanoma. (B) Post recurrence survival of melanoma patients showing low and high levels of NOTCH pathway members HES1 (left) and DLL3 (right). Previously published gene expression data of 44 metastatic melanoma tissue samples  were used to define “low” and “high” expressor groups (upper panels, Wilcoxon test, ***p<0.001) and to generate Kaplan-Meier curves (lower panels, log-rank test).
The aggressiveness of melanoma, which is surprisingly high considering that it is among a handful of cancers whose dimensions are reported in millimeters, is due to the high degree of heterogeneity and plasticity combined with the chemoresistance of melanoma cells , , . Therefore, new treatment strategies that selectively target the most resistant cells within the tumors, potentially the stem cell-like melanoma initiating cells, are urgently needed , .
RO4929097 has been previously shown to be a potent and selective gamma secretase inhibitor with promising antitumoral activity in vivo and without the toxicity associated with other gamma secretase inhibitors . Here, RO4929097 was shown for the first time to affect the tumor initiating ability of melanoma cells. We found that RO4929097 suppresses the oncogenic properties of several primary melanoma cell lines, as indicated by the decrease in proliferation and in the number of colonies formed in soft agar by RO4929097-treated cells. More importantly, we found that RO4929097 impairs the formation of melanospheres (Figure 1). In order to confirm in vivo that RO4929097 can affect the tumor initiating ability of melanoma cells, we used the serial xenotransplantation assay. This assay is the gold standard in assessing self-renewal, which is the defining property of cancer stem cells . Strikingly, the serial xenotransplantation assay showed a significant delay in tumor formation by the RO4929097-treated cells compared to the vehicle-treated ones (Figure 2). The decrease in size and incidence and the increase in latency of the secondary tumors formed by RO4929097-treated cells are particularly remarkable since we did not sort these cells for any specific marker, such as CD271 and ABCB5 , . Individual markers of tumor initiating cells have been challenged by the experimental evidence that most melanoma cells harbor tumorigenic capacity, irrespective of their phenotypic characteristics . Our data indicating that RO4929097 can affect the tumorigenicity of melanoma cells further support the inhibition of NOTCH signaling as a promising therapeutic strategy for the eradication of melanoma, as suggested for breast cancer and glioma , , .
Although it is important to understand alterations essential to primary transformation, the clinical obstacle in melanoma treatment is the dearth of effective therapeutics in the metastatic setting. In addition to its role in melanomagenesis, aberrant NOTCH signaling has been shown to promote metastasis in melanoma and other cancers , . Due to all these findings, we decided to test the efficacy of RO4929097 in vivo on metastatic melanoma cell lines. We observed that RO4929097 not only interferes with the ability of metastatic melanoma cells to form tumors when injected into nude mice, but also impairs the growth of pre-existing tumors (Figure 3). All together, these data lend further support to the notion that NOTCH signaling can play a role in advanced melanoma and offer a rationale to explore the therapeutic potential of NOTCH inhibition in the metastatic setting.
Finally, the analysis of gene expression arrays recently published by our group and others showed that several NOTCH signaling pathway components are overexpressed in metastatic cell lines in comparison to melanocytes. Furthermore, we report for the first time that aberrant NOTCH signaling can predict clinical outcome in melanoma, with high HES1 and DLL3 levels associated with shorter post recurrence survival (Figure 4). These results are in agreement with data previously reported in other tumor types, such as breast cancer ,  and neuroblastoma .
Molecular classification of melanoma is an emerging theme in melanoma therapeutics, with BRAF and c-KIT mutation status determining novel treatment options , . Although RO4929097 shows antitumor activity in both primary and metastatic cell lines, response to RO4929097 is not universal. Not all melanoma cell lines are (equally) sensitive in all the assays, as exemplified by the fact that some of the melanoma cell lines we tested were not responsive to the compound (data not shown) and by the different degree of reduction in proliferation and colony formation in soft agar showed by the 5 responsive cell lines reported in Figure 1. This differential sensitivity may be dependent on a unique molecular signature. The signature of responders to RO4929097 will emerge as clinical data accumulate from ongoing trials with this compound in melanoma, and will help to define the subset of patients that will benefit the most from RO4929097 treatment. These studies may also help to conceive combinatorial treatments of RO4929097, which, even when effective, does not cause a profound inhibition of tumor growth (Figure 1B, 2A, 3A, 3C), but is able to affect tumor initiating ability (Figure 2D), with other drugs that, conversely, are more effective at preventing tumor growth, but fail to decrease the tumor initiating ability. Alternatively, RO4929097 could also be effective in the adjuvant setting to prevent metastatic spread.
In summary, our preclinical studies support the gamma secretase inhibition as a novel approach that is able to target the melanoma initiating pool and offer insights into the clinical potential of this new treatment strategy.
Materials and Methods
Human melanoma cell lines
Primary melanoma cell lines WM35, WM98.1, WM115, WM983A and WM3248 were purchased from the Wistar Institute (Philadelphia, PA) and cultured in Mel 2% medium . A375 metastatic melanoma cell line was purchased from ATCC and cultured in DMEM +10% FBS. WM239A/131/4-5B1 (5B1) metastatic melanoma cell line, a kind gift from Robert S. Kerbel (University of Toronto), was cultured in DMEM+10% FBS.
Quantitative real time PCR (qRT-PCR)
Total RNA was extracted using Trizol reagent according to the manufacturer's instructions. It was then subjected to DNase treatment and retrotranscription (1ug RNA in a 20 ul reaction). Real-time PCR of HES1, HEY1, CD166, CD271, and JARID1B was performed using Sybr green fluorescence. 2 ul of RT were used in a 20 ul reaction. GAPDH was used as an internal standard. Relative quantification of gene expression was performed with the comparative CT method . The sequences of the primers used are described in Table S1.
Cells were seeded at 2.5×103 cells per well on a 12-well dish in triplicate. The day after (day 0), the medium was replaced, and DMSO or 10 uM RO4929097 was added and changed every 3–4 days. At the indicated time points, cells were fixed in 10% formalin solution and stored in PBS at 4°C. At day 18–24, all the plates were stained with crystal violet. After color elution with 10% acetic acid, optical density was read at 590 nm. A representative curve of three independent experiments is reported.
Growth in semisolid medium
The bottom layer was obtained by covering 6-well dishes with 3 ml of 0.6% agar in MCDB 153 medium . The day after, 5×104 cells pre-treated for 24 h with 10 uM RO4929097 or vehicle were seeded in triplicate in 2 ml Mel 2% medium containing 0.3% agar and 10 uM RO4929097 or vehicle. Colonies were counted after 3–4 weeks.
Melanosphere formation assay
Cells were seeded at a density of 5×105 per 6 cm dish in Mel 2% medium. The day after, the medium was switched to ES cell medium (hESCM4, Invitrogen) containing either DMSO or 10 uM RO4929097. The medium was left unchanged for two weeks, and then half of the medium was changed once a week, refreshing the drug. Spheres were visible in the DMSO treated dishes after 6–12 weeks.
Serial xenotransplantation assay of WM3248 cells
5×106 WM3248 primary melanoma cells were injected in the flank of NOG mice (n = 20). Once the tumors became measurable, mice were randomized in two groups and vehicle (n = 10) or RO4929097 (n = 10) was administered orally at 10 mg/Kg/day according to the protocol described in . Tumor volume was measured every 2–3 days for a total of 30 days (Figure S2A). At the end of the treatment period, tumors were excised and weighed. A piece of the excised tumors was cut and used for RNA extraction and qRT-PCR. The rest of the tumor was mechanically dissociated and passed through 100 um and 40 um strainers (BD Falcon). Viable cells were counted and 105 and 104 cells were re-injected in the flanks of NOG mice (n = 8) without any further treatment with RO4929097. At the indicated time points, the presence of tumor was checked. Tumor volume was measured every 2–3 days starting at 30 days post injection. At 45 days after the injection, tumors were excised and the weight was measured.
Xenograft assay of 5B1 and A375 cells
106 5B1 cells were injected in the flank of NOG mice (n = 20). Before tumors became measurable, mice were randomized in two groups and vehicle (n = 10) or RO4929097 (n = 10) was administered orally at 10 mg/Kg/day for 12 days (Figure S2B). Twenty-five days after the end of the treatment, tumor were excised, formalin fixed and paraffin embedded.
2×106 A375 cells were injected in the flanks of NOG mice (n = 12). As soon as tumors became measurable (60–100 mm3), mice were randomized in two groups, and vehicle (n = 6) or RO4929097 (n = 6) was administered orally at 10 mg/Kg/day for 2 weeks (Figure S2C). Tumor volume was measured every 2–3 days during the two weeks of treatment. Tumor weight was measured when the tumors were excised at the end of the 2 weeks of treatment.
Experiments were conducted following protocols approved by the NYU Institutional Animal Care Use Committee (IACUC) (protocol number 080109).
Ki-67 IHC was performed using mouse anti-human Ki-67 monoclonal antibody (Neomarkers/Lab Vision, Fremont, CA, USA). Sections were deparaffinized in xylene (3 changes), rehydrated through graded alcohols (3 changes 100% ethanol, 3 changes 95% ethanol) and rinsed in distilled water. Heat-induced epitope retrieval was performed in a 1200-Watt microwave oven at 100% power in 10 mM citrate buffer pH 6.0 for 20 min. Sections were allowed to cool down for 30 min and then rinsed in distilled water. Antibody incubation and detection were carried out at 37°C on a NEXes instrument (Ventana Medical Systems Tucson, Arizona) using Ventana's reagent buffer and detection kits. Endogenous peroxidase activity was blocked with hydrogen peroxide. Ki-67 was diluted 1∶400 and incubated for 30 min at room temperature. Biotinylated goat anti-mouse followed by application of streptavidin-horseradish-peroxidase conjugate was used to detect the primary antibody. The complex was visualized with 3,3-diaminobenzidene and enhanced with copper sulfate. Slides were washed in distilled water, counterstained with hematoxylin, dehydrated and mounted with permanent media. Appropriate positive controls were included with the study sections. Blinded to mouse groups, an attending pathologist (F.D.) scored the percentage of Ki-67-positive cells in each slide.
Analysis of previously published datasets
Gene expression data of 44 metastatic melanoma tissue samples previously published by our group  were used to define “low” and “high” expressor groups for HES1 and DLL3 (Wilcoxon test) and to generate Kaplan-Meier curves (log-rank test). The binary classification of gene expression uses a cut-off point derived using the statistical method described in , which is based on maximizing the absolute value of log-rank statistic. Expression values for both HES1 and DLL3 are statistically significant as continuous predictors of survival in Cox proportional hazard regression models (p values<0.03).
Primary melanoma cell lines form spheres when switched to ES medium. WM35, WM98.1, WM115, WM983A and WM3248 (left panels) organize in three-dimensional melanospheres (right panels, arrows) when switched to ES medium.
Schemes of drug treatment and toxicity. (A) Scheme of treatment for WM3248 xenograft. 5×106 WM3248 primary melanoma cells were injected in the flanks of NOG mice (10 per group). Once tumors were measurable, vehicle or RO4929097 was administered orally at 10 mg/Kg/day for 30 days. At day 42, mice were sacrificed and the tumors dissected and mechanically dissociated. 104 and 105 cells from vehicle and compound treated tumors were injected in the flank of NOG mice (8 flanks/group) and tumor formation was followed for 45 days. (B) Scheme of treatment for 5B1 xenograft. 106 5B1 metastatic melanoma cells were injected in the flank of NOG mice (10 per group). Before tumors became measurable, vehicle or RO4929097 was administered orally at 10 mg/Kg/day for 12 days. Treatment was stopped and tumor volume was started to be measured. (C) Scheme of treatment for A375 xenograft. 2×106 A375 metastatic melanoma cells were injected in the flank of NOG mice (6 per group). After the tumor became measurable, vehicle or RO4929097 was administered orally at 10 mg/Kg/day for 2 weeks.
Toxicity of RO4929097. Throughout the treatment period, mice treated with RO4929097 (black circles) did not show any weight loss compared with the vehicle treated ones (white circles).
Expression of Notch related genes in previously published data sets. (A) mRNA expression of the NOTCH ligand DLL3 (left) and the NOTCH target gene HEY1 (right). One-way variance ANOVA test was applied. (B) mRNA expression of the ligand DLL3 (up, left) and the targets HEY1 (up, right), HEY2 (down, left) and N-Cadherin (down, right). Unpaired t test with Welch's correction was applied. NHEM indicates the expression in the melanocytic lineage.
We thank the NYU Histopathology and Immunohistochemistry cores (supported in part by NIH/NCI P30 CA016087-30 grant at the NYU Cancer Institute) for tissue processing and histological staining, and Robert S. Kerbel (University of Toronto) for providing us WM239/131/4-5B1 (5B1) cells.
Conceived and designed the experiments: CH LP MFS JFB AP IO EH. Performed the experiments: CH LP MFS RM AH SM FD. Analyzed the data: CH LP MFS IO EH. Contributed reagents/materials/analysis tools: SS YS. Wrote the paper: CH LP MFS IO EH.
- 1. Garbe C, Leiter U (2009) Melanoma epidemiology and trends. Clin Dermatol 27: 3–9.
- 2. Molife R, Hancock BW (2002) Adjuvant therapy of malignant melanoma. Crit Rev Oncol Hematol 44: 81–102.
- 3. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, et al. (2004) A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 10: 1670–1677.
- 4. Ko JM, Fisher DE (2011) A new era: melanoma genetics and therapeutics. J Pathol 223: 241–250.
- 5. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, et al. (2011) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968–972.
- 6. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973–977.
- 7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507–2516.
- 8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711–723.
- 9. Poulikakos PI, Rosen N (2011) Mutant BRAF melanomas–dependence and resistance. Cancer Cell 19: 11–15.
- 10. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517–2526.
- 11. Miele L, Golde T, Osborne B (2006) Notch signaling in cancer. Curr Mol Med 6: 905–918.
- 12. Balint K, Xiao M, Pinnix CC, Soma A, Veres I, et al. (2005) Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest 115: 3166–3176.
- 13. Pinnix CC, Lee JT, Liu ZJ, McDaid R, Balint K, et al. (2009) Active Notch1 confers a transformed phenotype to primary human melanocytes. Cancer Res 69: 5312–5320.
- 14. Liu ZJ, Xiao M, Balint K, Smalley KS, Brafford P, et al. (2006) Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res 66: 4182–4190.
- 15. Bedogni B, Warneke JA, Nickoloff BJ, Giaccia AJ, Powell MB (2008) Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest 118: 3660–3670.
- 16. Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit LM, et al. (2010) Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 70: 10340–10350.
- 17. Thurber AE, Douglas G, Sturm EC, Zabierowski SE, Smit DJ, et al. (2011) Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene 30: 3036–3048.
- 18. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, et al. (2010) Targeting notch to target cancer stem cells. Clin Cancer Res 16: 3141–3152.
- 19. Boiko AD, Razorenova OV, van de Rijn M, Swetter SM, Johnson DL, et al. (2010) Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466: 133–137.
- 20. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, et al. (2008) Identification of cells initiating human melanomas. Nature 451: 345–349.
- 21. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, et al. (2010) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583–594.
- 22. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, et al. (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18: 510–523.
- 23. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, et al. (2008) Efficient tumour formation by single human melanoma cells. Nature 456: 593–598.
- 24. Shackleton M, Quintana E (2010) Progress in understanding melanoma propagation. Mol Oncol 4: 451–457.
- 25. Qin JZ, Stennett L, Bacon P, Bodner B, Hendrix MJ, et al. (2004) p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther 3: 895–902.
- 26. Shih Ie M, Wang TL (2007) Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res 67: 1879–1882.
- 27. Luistro L, He W, Smith M, Packman K, Vilenchik M, et al. (2009) Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 69: 7672–7680.
- 28. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, et al. (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328–9337.
- 29. Cheli Y, Giuliano S, Botton T, Rocchi S, Hofman V, et al. (2011) Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny. Oncogene 30: 2307–2318.
- 30. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, et al. (2007) Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20: 102–107.
- 31. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, et al. (2006) Cancer stem cells–perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 66: 9339–9344.
- 32. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, et al. (2005) Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 11: 7234–7242.
- 33. Riker AI, Enkemann SA, Fodstad O, Liu S, Ren S, et al. (2008) The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 1: 13.
- 34. Rose AE, Poliseno L, Wang J, Clark M, Pearlman A, et al. (2010) Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression. Cancer Res 71: 2561–2571.
- 35. Massi D, Tarantini F, Franchi A, Paglierani M, Di Serio C, et al. (2006) Evidence for differential expression of Notch receptors and their ligands in melanocytic nevi and cutaneous malignant melanoma. Mod Pathol 19: 246–254.
- 36. Hoek K, Rimm DL, Williams KR, Zhao H, Ariyan S, et al. (2004) Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. Cancer Res 64: 5270–5282.
- 37. Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, et al. (2009) Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A 106: 20429–20434.
- 38. La Porta CA (2009) Mechanism of drug sensitivity and resistance in melanoma. Curr Cancer Drug Targets 9: 391–397.
- 39. Postovit LM, Margaryan NV, Seftor EA, Hendrix MJ (2008) Role of nodal signaling and the microenvironment underlying melanoma plasticity. Pigment Cell Melanoma Res 21: 348–357.
- 40. Schatton T, Frank MH (2008) Cancer stem cells and human malignant melanoma. Pigment Cell Melanoma Res 21: 39–55.
- 41. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445: 851–857.
- 42. Kwong L, Chin L, Wagner SN (2007) Growth factors and oncogenes as targets in melanoma: lost in translation? Adv Dermatol 23: 99–129.
- 43. Gilbert CA, Daou MC, Moser RP, Ross AH (2010) Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res 70: 6870–6879.
- 44. Grudzien P, Lo S, Albain KS, Robinson P, Rajan P, et al. (2010) Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res 30: 3853–3867.
- 45. Hovinga KE, Shimizu F, Wang R, Panagiotakos G, Van Der Heijden M, et al. (2010) Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 28: 1019–1029.
- 46. Sethi N, Dai X, Winter CG, Kang Y (2011) Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 19: 192–205.
- 47. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, et al. (2005) High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 65: 8530–8537.
- 48. Yao K, Rizzo P, Rajan P, Albain K, Rychlik K, et al. (2011) Notch-1 and Notch-4 Receptors as Prognostic Markers in Breast Cancer. Int J Surg Pathol.
- 49. Chang HH, Lee H, Hu MK, Tsao PN, Juan HF, et al. (2010) Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma. Clin Cancer Res 16: 4411–4420.
- 50. Handolias D, Hamilton AL, Salemi R, Tan A, Moodie K, et al. (2010) Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 102: 1219–1223.
- 51. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809–819.
- 52. Drabkin HA, Parsy C, Ferguson K, Guilhot F, Lacotte L, et al. (2002) Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia 16: 186–195.
- 53. Klein JP (2002) Survival analysis methods in cancer studies. Cancer Treat Res 113: 37–57.